96 Tests PN: B113200
45x Ab-conjugated beads (S4P4 - human sRANKL Ab-bead). PN: B113200A. One vial containing 100 µL of anti-human sRANKL conjugated to AimPlex Bead S4P4.
25x Biotin-detection Ab (human sRANKL Biotin-dAb). PN: B113200B. One vial containing 100 µL of biotinylated anti-human sRANKL.
Lyophilized Standard Mix-Human Group 5 Panel B, 10-Plex. PN: HG50010. One vial containing lyophilized recombinant human sRANKL, sEndoglin, sVCAM-1, sE-selectin, sCD95L, sICAM-1, sCD25, sCD14, sTNFRI, and sCD40L. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.
Application: Optimal antibody pair and antigen standard for assaying human TNFSF11/sCD254/RANKL. Can be multiplexed with other analytes in Human Group 5. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
Storage: 2-8 C in the dark.
Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
For Research Use Only. Not for use in diagnostic procedures.
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 5 pg/mL
LLOQ: < 10 pg/mL
ULOQ: > 5,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Cross-reactivity of analytes in Human Group 5: Negligible
Sample volume: 15 µL/test
Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as Tumor Necrosis Factor Ligand Super Family Member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL) and CD254, is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL has been identified to affect the immune system and control bone regeneration and remodeling. RANKL is expressed in several tissues and organs including: skeletal muscle, thymus, liver, colon, small intestine, adrenal gland, osteoblast, mammary gland epithelial cells, prostate and pancreas. Variation in concentration levels of RANKL throughout several organs, reconfirm the uses and importance of bone growth and immune functions within the body. Overproduction of RANKL is implicated in a variety of degenerative bone diseases, such as rheumatoid arthritis and psoriatic arthritis. Diseases associated with TNFSF11 include osteopetrosis, autosomal recessive 2 and tnfsf11-related autosomal recessive osteopetrosis.
Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN, Lee SY, Choi Y (October 1997). "TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells". J. Biol. Chem. 272 (40): 25190–4. doi:10.1074/jbc.272.40.25190. PMID 9312132.
Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (November 1997). "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function". Nature 390 (6656): 175–9. doi:10.1038/36593. PMID 9367155.
Hanada R, Hanada T, Sigl V, Schramek D, Penninger JM (2011). "RANKL/RANK-beyond bones". J. Mol. Med. 89 (7): 647–56. doi:10.1007/s00109-011-0749-z. PMID 21445556.
Mueller CG, Hess E (2012). "Emerging Functions of RANKL in Lymphoid Tissues". Front Immunol 3: 261. doi:10.3389/fimmu.2012.00261. PMC 3432452. PMID 229697